Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Ariosa Diagnostics
Evaluate
July 27, 2016
LabCorp takes Sequenom for $300m
January 21, 2016
The medtech IPO window swings shut
January 11, 2016
Thermo kicks off 2016’s medtech megamergers
August 28, 2015
Acelity files to float, but is it secretly seeking a buyer?
August 13, 2015
Roche sets an example with GeneWeave acquisition
December 02, 2014
Roche seeks Harmony with Ariosa buy
May 08, 2014
Medtech convulsed by IPO frenzy
November 04, 2013
Sequenom becomes second casualty of Myriad ruling
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 17, 2023
PD(L)anner – February 2023
February 09, 2023
Biopharma and Medtech Review 2022
Editor's Picks
March 13, 2023
Silicon Valley Bank: biopharma’s latest crisis
March 13, 2023
Pfizer rescues biotech
February 28, 2023
Why Pfizer (and others) will be interested in Seagen
March 04, 2023
ACC 2023 – Esperion’s outcomes win looks lacklustre
March 06, 2023
T-cell receptor behemoths consolidate? Not quite
